Publisher’s Response:
Thank you, Dr. Levy, for setting me straight on the facts of the Women’s Health Initiative. The WHI trial did demonstrate an increase in breast cancer incidence in women treated with estrogen and progestogen, Premarin, and Provera. For much of orthodox medicine, this translates to hormone replacement therapy of estrogen and progesterone increases the risk for developing breast cancer. The results of the combination therapy stand sharply in contract to the MISSION study, which found that a combination of estradiol and bioidentical progesterone did not increase the risk of breast cancer. Admittedly, the WHI study was a randomized controlled trial and the MISSION study was a prospective study.
The main culprit appears to be the use of a progestogen, a synthetic form of progesterone, in increasing the risk for breast cancer. It is interesting that the WHI study arm using estrogen or Premarin alone found no increase in breast cancer risk. It has been long observed that estrogen treatment given without progesterone as hormone replacement appears to increase the risk of uterine cancer. Hence, the question of hormone safety depends on combination of estrogen and progesterone treatment.
Dr. Jonathan Wright points out that Premarin contains a minimal amount of estradiol and primarily contains conjugated equine estrogens, which are not natural to the human female. It would appear that the WHI study arm of estrogen-treatment-only demonstrates that horse estrogens are not significantly increasing the risk of breast cancer in humans.
Jonathan Collin, MD









0 Comments